影音aV 影 先鋒A v電影 Our DMPK group has developed a comprehensive set of assays to characterize and assess the drug-like properties of project compounds. To select the best candidates for advancement, we optimize the structural properties to improve clinical pharmacokinetic (PK) outcomes, providing quick turnaround of data to speed compound progression. We also leverage state-of-the-art platforms such as liquid chromatography/mass spectrometry (LC/MS) to reliably identify and quantitate solutions for your most complex molecular challenges.

影音aV 影 先鋒A v電影 We offer the following assays:

SELECTED ASSAYS FOR GUIDING COMPOUND PROGRESSION

Hit to LeadLead OptimizationCandidate SelectionIND-Enabling
SolubilityPlasma protein bindingReactive metabolitesCYP inhibition
PAMPA permeabilityCYP inhibition-LC/MS/MShERG inhibitionCYP induction
Metabolic stability/clearanceCell-based permeability: MDR1-MDCK, Caco-2Non-GLP Ames testCYP reaction phenotyping
CYP inhibition, fluorescenceMetabolite profiling and IDIn vivo metabolite IDSpecies comparison of metabolic pathways
Chemical stabilityIn vivo PK and bioanalysisHepatocyte metabolic clearance
Plasma stabilityCytotoxicity

LET’S GET STARTED